Phase 1 Refractory T-Cell Lymphoma Clinical Trials

2 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–2 of 2 trials

Recruiting

Phase 1

CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid LeukemiaRelapsed/Refractory T-cell Lymphoma

Second Affiliated Hospital, School of Medicine, Zhejiang University25 enrolled1 locationNCT06696846

Recruiting

Phase 1Phase 2

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Relapsed or Refractory T-cell Lymphomas

Bristol-Myers Squibb85 enrolled40 locationsNCT06035497